Qiagen NV

QGEN · NYSE

$48.90+$2.35 (+5.05%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $46.55

Latest news

NewsOct 20, 12:36 PM ET
'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg
Press releaseOct 13, 4:05 PM ETBusiness Wire
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
Press releaseOct 6, 4:05 PM ETBusiness Wire
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
Press releaseSep 28, 1:30 AM ETBusiness Wire
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
Press releaseSep 24, 4:05 PM ETBusiness Wire
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
Press releaseSep 18, 4:05 PM ETBusiness Wire
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
NewsAug 31, 1:47 PM ETVandana Singh
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
Press releaseAug 28, 2:38 PM ETPRNewswire
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Press releaseAug 27, 4:05 PM ETBusiness Wire
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
Press releaseAug 24, 9:47 AM ETBusiness Wire
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
Press releaseAug 10, 4:05 PM ETBusiness Wire
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
NewsAug 5, 4:12 PM ET
Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M Estimate
Press releaseAug 5, 4:05 PM ETBusiness Wire
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
Press releaseJul 15, 4:05 PM ETBusiness Wire
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
Press releaseJul 15, 8:48 AM ETBusiness Wire
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
Press releaseJul 14, 4:05 PM ETBusiness Wire
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
NewsJul 10, 9:26 AM ETVandana Singh
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
NewsJul 9, 10:18 AM ET
'Qiagen Draws Early Takeover Interest From EQT, Advent' - Bloomberg
Press releaseJun 15, 1:30 AM ETBusiness Wire
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
Press releaseJun 4, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Press releaseJun 2, 5:41 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Press releaseMay 28, 4:05 PM ETBusiness Wire
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
Press releaseMay 26, 5:35 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Press releaseMay 21, 8:00 PM ETGlobe Newswire
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
Press releaseMay 20, 4:05 PM ETBusiness Wire
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
Press releaseMay 20, 9:00 AM ETPRNewswire
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky
Press releaseMay 19, 7:00 PM ETBusiness Wire
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
Press releaseMay 19, 5:11 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Press releaseMay 19, 4:05 PM ETBusiness Wire
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
Press releaseMay 15, 10:47 AM ETGlobe Newswire
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
NewsApr 28, 3:43 PM ETPiero Cingari
Stock Market Today: S&P 500 Drops Amid Tech Sell-Off, Oil Climbs To $100 On Hormuz Drama
NewsJun 26, 1:22 PM ET
QIAGEN Elects Stephen Rusckowski As Chairman Of Supervisory Board; Shareholders Approve Annual Cash Dividend Of $0.25/Shr And Synthetic Share Repurchase Authorization Of Up To $500M
Press releaseJun 26, 1:16 PM ETBusiness Wire
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

Qiagen Q2 Adj. EPS $0.62 Beats $0.60 Estimate, Sales $535.000M Beat $527.484M Estimate

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover

'Qiagen Draws Early Takeover Interest From EQT, Advent' - Bloomberg

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows

Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky

QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm

Stock Market Today: S&P 500 Drops Amid Tech Sell-Off, Oil Climbs To $100 On Hormuz Drama

QIAGEN Elects Stephen Rusckowski As Chairman Of Supervisory Board; Shareholders Approve Annual Cash Dividend Of $0.25/Shr And Synthetic Share Repurchase Authorization Of Up To $500M

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board